Patient safety is our top priority, and we are committed to supporting the active fight against falsified Novo Nordisk medicines and other illegal activity in the market.
We are proactively combating falsified medicines. Through constantly reinforced security measures and collaboration with authorities and industry peers, we strive to protect patient’s health and ensure the integrity of our products.
16 May 2025
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
14 May 2025
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
12 May 2025
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.
We offer 878 job opportunities